Recurrent Pneumothorax after Etanercept Therapy in a Rheumatoid Arthritis Patient: A Case Report

다국어 초록 (Multilingual Abstract)

The use of anti-tumor necrosis factor (anti-TNF) agents for rheumatoid arthritis (RA)patients who are refractory to disease-modifying anti-rheumatic drugs is graduallyincreasing. Etanercept is the first anti-TNF agent to be approved for RA treatment andis also the most widely used. However, aggravation of interstitial lung disease afteretanercept treatment in RA patients has been reported recently. We report the firstcase of recurrent spontaneous pneumothorax with progression of interstitial lung diseaseafter initiating etanercept therapy. The withdrawal of etanercept and a changeto adalimumab, a different class of TNF inhibitor, achieved clinical stabilization.

참고문헌 (Reference)

1 Khasnis AA, "Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk" 40 : 147-163, 2010

2 Piguet PF, "Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice" 7 : 515-518, 1994

3 Morjaria JB, "The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial" 63 : 584-591, 2008

4 Fries JF, "Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies" 39 : 616-622, 1996

5 Thavarajah K, "Pulmonary complications of tumor necrosis factor-targeted therapy" 103 : 661-669, 2009

6 Hadjinicolaou AV, "Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review" 50 : 2297-2305, 2011

7 Peno-Green L, "Lung injury linked to etanercept therapy" 122 : 1858-1860, 2002

8 Allen JT, "Growth factors in idiopathic pulmonary fibrosis:relative roles" 3 : 13-, 2002

9 Jarvis B, "Etanercept: a review of its use in rheumatoid arthritis" 57 : 945-966, 1999

10 Hagiwara K, "Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis" 34 : 1151-1154, 2007